Tempus AI Inc
TEM76.840USD
+0.780+1.03%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
13.66BMarket Cap
LossP/E TTM
More Details of Tempus AI Inc Company
Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
Tempus AI Inc Info
Ticker SymbolTEM
Company nameTempus AI Inc
IPO dateJun 14, 2024
CEOMr. Eric P. Lefkofsky, J.D.
Number of employees2400
Security typeOrdinary Share
Fiscal year-endJun 14
Address600 West Chicago Avenue
CityCHICAGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code60654
Phone18009765448
Websitehttps://www.tempus.com/
Ticker SymbolTEM
IPO dateJun 14, 2024
CEOMr. Eric P. Lefkofsky, J.D.
Company Executives of Tempus AI Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Ryan Fukushima
Mr. Ryan Fukushima
Chief Operating Officer
Chief Operating Officer
877.22K
-1.14%
Mr. Peter J. Barris
Mr. Peter J. Barris
Independent Director
Independent Director
102.70K
-1.27%
Mr. Eric D. Belcher
Mr. Eric D. Belcher
Independent Director
Independent Director
14.71K
-11.95%
Mr. Andrew (Andy) Polovin
Mr. Andrew (Andy) Polovin
Executive Vice President, General Counsel, Company Secretary
Executive Vice President, General Counsel, Company Secretary
10.43K
-19.01%
Mr. James (Jim) Rogers
Mr. James (Jim) Rogers
Chief Financial Officer
Chief Financial Officer
5.48K
-75.79%
Mr. David R. Epstein
Mr. David R. Epstein
Independent Director
Independent Director
3.86K
-8.74%
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
1.25K
-61.50%
Dr. Jennifer A. Doudna, Ph.D.
Dr. Jennifer A. Doudna, Ph.D.
Independent Director
Independent Director
--
--
Mr. Theodore John (Ted) Leonsis
Mr. Theodore John (Ted) Leonsis
Independent Director
Independent Director
--
--
Dr. Nadja Y. West, M.D.
Dr. Nadja Y. West, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ryan Fukushima
Mr. Ryan Fukushima
Chief Operating Officer
Chief Operating Officer
877.22K
-1.14%
Mr. Peter J. Barris
Mr. Peter J. Barris
Independent Director
Independent Director
102.70K
-1.27%
Mr. Eric D. Belcher
Mr. Eric D. Belcher
Independent Director
Independent Director
14.71K
-11.95%
Mr. Andrew (Andy) Polovin
Mr. Andrew (Andy) Polovin
Executive Vice President, General Counsel, Company Secretary
Executive Vice President, General Counsel, Company Secretary
10.43K
-19.01%
Mr. James (Jim) Rogers
Mr. James (Jim) Rogers
Chief Financial Officer
Chief Financial Officer
5.48K
-75.79%
Mr. David R. Epstein
Mr. David R. Epstein
Independent Director
Independent Director
3.86K
-8.74%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Blue Media, LLC
10.49%
BK TL21 LLC
8.80%
Lefkofsky (Eric Paul)
6.77%
Baillie Gifford & Co.
5.61%
The Vanguard Group, Inc.
5.45%
Other
62.88%
Shareholders
Shareholders
Proportion
Blue Media, LLC
10.49%
BK TL21 LLC
8.80%
Lefkofsky (Eric Paul)
6.77%
Baillie Gifford & Co.
5.61%
The Vanguard Group, Inc.
5.45%
Other
62.88%
Shareholder Types
Shareholders
Proportion
Corporation
29.32%
Investment Advisor
28.41%
Investment Advisor/Hedge Fund
11.27%
Individual Investor
7.52%
Research Firm
5.19%
Hedge Fund
4.31%
Holding Company
3.13%
Venture Capital
0.91%
Bank and Trust
0.88%
Other
9.06%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
619
75.72M
43.81%
-4.20M
2025Q2
501
136.83M
81.41%
-3.18M
2025Q1
444
136.54M
81.24%
-3.30M
2024Q4
259
141.87M
89.45%
+26.80M
2024Q3
171
136.39M
89.94%
+26.38M
2024Q2
115
132.44M
88.72%
+132.44M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Blue Media, LLC
18.14M
10.75%
-7.69M
-29.78%
Aug 08, 2025
BK TL21 LLC
15.22M
9.02%
--
--
Mar 18, 2025
Lefkofsky (Eric Paul)
11.72M
6.95%
+7.18M
+158.25%
Aug 29, 2025
Baillie Gifford & Co.
12.09M
7.17%
-196.93K
-1.60%
Jun 30, 2025
The Vanguard Group, Inc.
7.72M
4.58%
+1.72M
+28.73%
Jun 30, 2025
Gray Media, LLC
9.27M
5.5%
-133.25K
-1.42%
Aug 08, 2025
Red Sky LLC
9.50M
5.63%
-2.06M
-17.83%
Mar 31, 2025
ARK Investment Management LLC
7.42M
4.4%
-79.63K
-1.06%
Jun 30, 2025
SoftBank Group Corp
5.41M
3.2%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.13M
1.85%
+2.58M
+467.49%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ARK Genomic Revolution ETF
10.53%
Global X HealthTech ETF
6.29%
ARK Innovation ETF
5.71%
Renaissance IPO ETF
3.91%
Franklin Genomic Advancements ETF
3.64%
KraneShares Artificial Intelligence and Tcnlgy ETF
3.46%
First Trust Health Care Alphadex Fund
2.69%
AXS Green Alpha ETF
2.55%
ROBO Global Artificial Intelligence ETF
2.51%
ROBO Global Healthcare Technology & Innovation ETF
1.94%
View more
ARK Genomic Revolution ETF
Proportion10.53%
Global X HealthTech ETF
Proportion6.29%
ARK Innovation ETF
Proportion5.71%
Renaissance IPO ETF
Proportion3.91%
Franklin Genomic Advancements ETF
Proportion3.64%
KraneShares Artificial Intelligence and Tcnlgy ETF
Proportion3.46%
First Trust Health Care Alphadex Fund
Proportion2.69%
AXS Green Alpha ETF
Proportion2.55%
ROBO Global Artificial Intelligence ETF
Proportion2.51%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.94%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Tempus AI Inc?
The top five shareholders of Tempus AI Inc are:
Blue Media, LLC holds 18.14M shares, accounting for 10.75% of the total shares.
BK TL21 LLC holds 15.22M shares, accounting for 9.02% of the total shares.
Lefkofsky (Eric Paul) holds 11.72M shares, accounting for 6.95% of the total shares.
Baillie Gifford & Co. holds 12.09M shares, accounting for 7.17% of the total shares.
The Vanguard Group, Inc. holds 7.72M shares, accounting for 4.58% of the total shares.
Blue Media, LLC holds 18.14M shares, accounting for 10.75% of the total shares.
BK TL21 LLC holds 15.22M shares, accounting for 9.02% of the total shares.
Lefkofsky (Eric Paul) holds 11.72M shares, accounting for 6.95% of the total shares.
Baillie Gifford & Co. holds 12.09M shares, accounting for 7.17% of the total shares.
The Vanguard Group, Inc. holds 7.72M shares, accounting for 4.58% of the total shares.
What are the top three shareholder types of Tempus AI Inc?
The top three shareholder types of Tempus AI Inc are:
Blue Media, LLC
BK TL21 LLC
Lefkofsky (Eric Paul)
Blue Media, LLC
BK TL21 LLC
Lefkofsky (Eric Paul)
How many institutions hold shares of Tempus AI Inc (TEM)?
As of 2025Q3, 619 institutions hold shares of Tempus AI Inc, with a combined market value of approximately 75.72M, accounting for 43.81% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -37.61%.
What is the biggest source of revenue for Tempus AI Inc?
In --, the -- business generated the highest revenue for Tempus AI Inc, amounting to -- and accounting for --% of total revenue.
